Cargando…

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer

PURPOSE: To review the clinical data and treatment efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 96 patients with mCRC treated by chemotherapy plus bevacizumab in the PLA General Hospital between December 2005 and August 2012 w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Qian, Shi, Yan, Chen, Li, Xiao, Xiaoyi, Dai, Guanghai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643288/ https://www.ncbi.nlm.nih.gov/pubmed/23671391 http://dx.doi.org/10.2147/OTT.S41449

Ejemplares similares

Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial
por: Wang, Fenghua, et al.
Publicado: (2021)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
por: Guan, Zhong-Zhen, et al.
Publicado: (2011)

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
por: Novillo, Apolonia, et al.
Publicado: (2020)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients
por: Sun, De-cong, et al.
Publicado: (2017)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
por: Xu, Ran, et al.
Publicado: (2018)

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
por: Gou, Miaomiao, et al.
Publicado: (2018)

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Liu, Ningning, et al.
Publicado: (2020)

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
por: Jiang, Chang, et al.
Publicado: (2017)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study
por: Lu, Linbin, et al.
Publicado: (2019)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
por: van Nassau, Sietske C., et al.
Publicado: (2021)

Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer
por: Hagman, Helga, et al.
Publicado: (2018)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS‐mutant metastatic colorectal cancer
por: Huang, Weizhen, et al.
Publicado: (2022)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
por: Hansen, T F, et al.
Publicado: (2015)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
por: Dinu, Ioana Mihaela, et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
por: Katada, Eiichi, et al.
Publicado: (2018)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
por: Ocvirk, Janja, et al.
Publicado: (2016)

Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis
por: Ilic, Irena, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_38jicpuht2sq57lui8bm2ud64b